Advanced Proteome Therapeutics Past Earnings Performance
Past criteria checks 0/6
Advanced Proteome Therapeutics's earnings have been declining at an average annual rate of -5.7%, while the Biotechs industry saw earnings growing at 16.9% annually.
Key information
-5.7%
Earnings growth rate
12.7%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Apr 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Advanced Proteome Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Apr 23 | 0 | -2 | 0 | 1 |
| 31 Jan 23 | 0 | -1 | 0 | 1 |
| 31 Oct 22 | 0 | 0 | 0 | 1 |
| 31 Jul 22 | 0 | 1 | 0 | 1 |
| 30 Apr 22 | 0 | 1 | 0 | 1 |
| 31 Jan 22 | 0 | 0 | 0 | 1 |
| 31 Oct 21 | 0 | -1 | 0 | 1 |
| 31 Jul 21 | 0 | -2 | 0 | 0 |
| 30 Apr 21 | 0 | -2 | 1 | 0 |
| 31 Jan 21 | 0 | -1 | 1 | 0 |
| 31 Oct 20 | 0 | -1 | 1 | 0 |
| 31 Jul 20 | 0 | 0 | 1 | 0 |
| 30 Apr 20 | 0 | 0 | 1 | 0 |
| 31 Jan 20 | 0 | 0 | 1 | 0 |
| 31 Oct 19 | 0 | 0 | 1 | 0 |
| 31 Jul 19 | 0 | 0 | 1 | 0 |
| 30 Apr 19 | 0 | 0 | 1 | 0 |
| 31 Jan 19 | 0 | 0 | 1 | 0 |
| 31 Oct 18 | 0 | -1 | 1 | 0 |
| 31 Jul 18 | 0 | -1 | 1 | 0 |
| 30 Apr 18 | 0 | 0 | 1 | 0 |
| 31 Jan 18 | 0 | -1 | 1 | 0 |
| 31 Oct 17 | 0 | -1 | 1 | 0 |
| 31 Jul 17 | 0 | -1 | 1 | 0 |
| 30 Apr 17 | 0 | -1 | 1 | 0 |
| 31 Jan 17 | 0 | -1 | 1 | 0 |
| 31 Oct 16 | 0 | -1 | 1 | 0 |
| 31 Jul 16 | 0 | -1 | 1 | 0 |
| 30 Apr 16 | 0 | -1 | 1 | 0 |
| 31 Jan 16 | 0 | -1 | 1 | 0 |
| 31 Oct 15 | 0 | -1 | 1 | 0 |
| 31 Jul 15 | 0 | -1 | 1 | 0 |
| 30 Apr 15 | 0 | 0 | 1 | 0 |
| 31 Jan 15 | 0 | 0 | 1 | 0 |
| 31 Oct 14 | 0 | -1 | 1 | 0 |
| 31 Jul 14 | 0 | -1 | 1 | 0 |
| 30 Apr 14 | 0 | -2 | 1 | 0 |
| 31 Jan 14 | 0 | -2 | 1 | 0 |
| 31 Oct 13 | 0 | -1 | 1 | 0 |
| 31 Jul 13 | 0 | -1 | 1 | 0 |
Quality Earnings: 0E81 is currently unprofitable.
Growing Profit Margin: 0E81 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0E81 is unprofitable, and losses have increased over the past 5 years at a rate of 5.7% per year.
Accelerating Growth: Unable to compare 0E81's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0E81 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.2%).
Return on Equity
High ROE: 0E81's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.